Venezuela extends comment period for draft biosimilars guidance
This article was originally published in Scrip
Companies wishing to comment on the draft Venezuelan biosimilars guidance now have more time to do so, after the authorities extended the consultation period from mid-December to 28 February 2014. As well as explaining the preclinical and clinical requirements of the comparability exercise, the guidance allows for the extrapolation of indications provided certain criteria are met.
You may also be interested in...
The UK’s departure from the EU imposes a number of requirements on sponsors running EU trials, but it seems that many have still not taken steps to fall into line.
As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.
The International Coalition of Medicines Regulatory Authorities have sketched out the criteria that should be met before candidate coronavirus vaccines can proceed into late-stage trials, and agreed on how to design the studies and who should be included.